View Filing Data

Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014 shares
Document and Entity Information
Entity Registrant Name	AbbVie Inc.
Entity Central Index Key	0001551152
Document Type	10-Q
Document Period End Date	Mar. 31, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding	1,590,066,459
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	Q1

Condensed Consolidated Statements of Earnings (unaudited) - USD ($)
shares in Millions, $ in Millions

3 Months Ended

Mar. 31, 2014

Mar. 31, 2013

Condensed Consolidated Statements of Earnings (unaudited)

Net sales

$ 4,563

$ 4,329

Cost of products sold

1,100

1,153

Selling, general and administrative

1,340

1,237

Research and development

772

634

Total operating costs and expenses

3,212

3,024

Operating earnings

1,351

1,305

Interest expense, net

Net foreign exchange loss

Other income, net

(3)

(15)

Earnings before income tax expense

1,286

1,239

Income tax expense

306

271

Net earnings

$ 980

$ 968

Per share data

Basic earnings per share (in dollars per share)

$ 0.61

Diluted earnings per share (in dollars per share)

0.61

0.60

Cash dividends declared per common share (in dollars per share)

^[1]

$ 0.42

$ 0.80

Weighted-average basic shares outstanding (in shares)

1,595

1,588

Weighted-average diluted shares outstanding (in shares)

1,609

1,605

[1]

On January 4, 2013, the board of directors declared a cash dividend of $0.40 per share of common stock. This dividend was declared from pre-separation earnings and was recorded as a reduction of additional paid-in capital. In addition, AbbVie declared a regular cash dividend of $0.40 per share of common stock during the first quarter of 2013. Refer to Note 8 for information regarding cash dividends declared and paid during the first quarters of 2014 and 2013.

Condensed Consolidated Statements of Earnings (unaudited) (Parenthetical)

3 Months Ended

Mar. 31, 2013

$ / shares

Regular quarterly cash dividends (in dollars per share)

$ 0.40

Dividends declared (in dollars per share)

$ 0.80

^[1]

[1]

Condensed Consolidated Statements of Comprehensive Income (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements of Comprehensive Income (unaudited)
Net earnings	$ 980	$ 968
Foreign currency translation adjustments	(29)	(232)
Pension and post-employment benefits, net of tax expense of $4 and $9 for the three months ended March 31, 2014 and 2013, respectively	12	19
Unrealized losses on marketable equity securities		(1)
Hedging activities, net of tax expense of $2 and $2 for the three months ended March 31, 2014 and 2013, respectively	33	9
Other comprehensive income (loss)	16	(205)
Comprehensive income	$ 996	$ 763

Condensed Consolidated Statements of Comprehensive Income (unaudited) (Parenthetical) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Condensed Consolidated Statements of Comprehensive Income (unaudited)
Pension and post-employment benefits, tax expense	$ 4	$ 9
Hedging activities, tax expense	$ 2	$ 2

Condensed Consolidated Balance Sheets - USD ($) $ in Millions	Mar. 31, 2014	Dec. 31, 2013
Current assets
Cash and equivalents	$ 8,140	$ 9,595
Short-term investments	960	300
Accounts and other receivables, net	3,650	3,854
Inventories, net	1,104	1,150
Income tax receivable	940	949
Deferred income taxes	1,075	766
Prepaid expenses and other	1,460	1,234
Total current assets	17,329	17,848
Investments	119	118
Property and equipment, net	2,333	2,298
Intangible assets, net of amortization	1,802	1,890
Goodwill	6,271	6,277
Other assets	803	767
Total assets	28,657	29,198
Current liabilities
Short-term borrowings	2	413
Current portion of long-term debt and lease obligations	18	18
Accounts payable and accrued liabilities	6,196	6,448
Total current liabilities	6,216	6,879
Long-term liabilities	3,358	3,535
Long-term debt and lease obligations	14,386	14,292
Commitments and contingencies
Stockholders' equity
Common stock, $0.01 par value, authorized 4,000,000,000 shares, issued 1,603,660,660 and 1,594,260,996 shares in 2014 and 2013, respectively	16	16
Common stock held in treasury, at cost, 13,594,201 and 6,900,434 shares in 2014 and 2013, respectively	(672)	(320)
Additional paid-in-capital	3,905	3,671
Retained earnings	1,874	1,567
Accumulated other comprehensive loss	(426)	(442)
Total stockholders' equity	4,697	4,492
Total liabilities and equity	$ 28,657	$ 29,198

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2014	Dec. 31, 2013
Condensed Consolidated Balance Sheets
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	4,000,000,000	4,000,000,000
Common stock, issued (in shares)	1,603,660,660	1,594,260,996
Common stock held in treasury (in shares)	13,594,201	6,900,434

Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Cash flows from operating activities
Net earnings	$ 980	$ 968
Adjustments to reconcile net earnings to net cash from operating activities:
Depreciation	89	92
Amortization of intangible assets	110	135
Stock-based compensation	106	87
Other, net	(47)	14
Changes in operating assets and liabilities, net of acquisitions:
Accounts and other receivables	167	57
Inventories	50	11
Prepaid expenses and other assets	(219)	29
Accounts payable and other liabilities	(612)	(206)
Cash flows from operating activities	624	1,187
Cash flows from investing activities
Acquisitions of property and equipment	(137)	(88)
Purchases of investment securities	(660)
Sales and maturities of investment securities		1,575
Cash flows from investing activities	(797)	1,487
Cash flows from financing activities
Net change in short-term borrowings	(410)	(601)
Dividends paid	(641)	(636)
Purchases of treasury stock	(329)	(97)
Proceeds from the exercise of stock options	85	91
Net transactions with Abbott Laboratories, excluding noncash items		(242)
Other, net	18	(97)
Cash flows from financing activities	(1,277)	(1,582)
Effect of exchange rate changes on cash and equivalents	(5)	(14)
Net (decrease) increase in cash and equivalents	(1,455)	1,078
Cash and equivalents, beginning of period	9,595	5,901
Cash and equivalents, end of period	$ 8,140	$ 6,979

Background and Basis of Presentation	3 Months Ended
Background and Basis of Presentation	Mar. 31, 2014
Background and Basis of Presentation
Background and Basis of Presentation	Note 1 Background and Basis of Presentation Background The principal business of AbbVie Inc. (AbbVie or the company) is the discovery, development, manufacture and sale of a broad line of pharmaceutical products. Substantially all of AbbVie’s sales in the United States are to three wholesalers. Outside the U.S., products are sold primarily to health care providers or through distributors, depending on the market served. On January 1, 2013, AbbVie became an independent publicly-traded company as a result of the distribution by Abbott Laboratories (Abbott) of 100 percent of the outstanding common stock of AbbVie to Abbott’s shareholders (the separation). On January 1, 2013, Abbott’s shareholders of record as of the close of business on December 12, 2012 received one share of AbbVie common stock for every one share of Abbott common stock held as of the record date. AbbVie’s common stock began trading “regular-way” under the ticker symbol “ABBV” on the New York Stock Exchange on January 2, 2013. In connection with the separation, AbbVie and Abbott entered into transition services agreements covering certain corporate support and back office services that AbbVie has historically received from Abbott. Such services include information technology, accounts payable, payroll, receivables collection, treasury and other financial functions, as well as order entry, warehousing, engineering support, quality assurance support and other administrative services. These agreements facilitate the separation by allowing AbbVie to operate independently prior to establishing stand-alone back office functions across its organization. Transition services may be provided for up to 24 months post-separation, with an option for a one-year extension. During the first three months of 2014 and 2013, AbbVie incurred $80 million and $34 million of separation-related expenses, including legal, information technology and regulatory fees, which were principally classified in selling, general and administrative expenses (SG&A). Basis of Presentation The unaudited interim condensed consolidated financial statements of AbbVie have been prepared pursuant to the rules and regulations of the U.S. Securities and Exchange Commission. Accordingly, certain information and footnote disclosures normally included in annual financial statements prepared in accordance with generally accepted accounting principles in the U.S. (U.S. GAAP) have been omitted. These unaudited interim condensed consolidated financial statements should be read in conjunction with the company’s audited consolidated financial statements and notes included in the company’s Annual Report on Form 10-K for the year ended December 31, 2013. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the company’s financial position and operating results. Net sales and net earnings for any interim period are not necessarily indicative of future or annual results. For a certain portion of AbbVie’s operations, the legal transfer of AbbVie’s assets (net of liabilities) did not occur with the separation of AbbVie on January 1, 2013 due to the time required to transfer marketing authorizations and satisfy other regulatory requirements in certain countries. Under the terms of the separation agreement with Abbott, AbbVie is responsible for the business activities conducted by Abbott on its behalf, and is subject to the risks and entitled to the benefits generated by these operations and assets. As a result, the related assets and liabilities and results of operations have been reported in AbbVie’s condensed consolidated financial statements as of and for the three months ended March 31, 2014. Net sales related to these operations for the three months ended March 31, 2014 totaled approximately $67 million. At March 31, 2014, the assets and liabilities consisted primarily of accounts receivable of $68 million, inventories of $47 million, other assets of $63 million, and accounts payable and other accrued liabilities of $129 million. At December 31, 2013, the assets and liabilities consisted primarily of accounts receivable of $62 million, inventories of $190 million, other assets of $93 million and accounts payable and other accrued liabilities of $212 million. The majority of these operations are expected to be transferred to AbbVie by the end of 2015. As of March 31, 2014 and December 31, 2013, the aggregate amount due from Abbott totaled $540 million and $738 million, respectively, and was classified in accounts and other receivables, net, in the company’s condensed consolidated balance sheets. The aggregate amount due to Abbott totaled $517 million and $876 million as of March 31, 2014 and December 31, 2013, respectively, and was classified in accounts payable and accrued liabilities in the company’s condensed consolidated balance sheets.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-URI http://asc.fasb.org/subtopic&trid=2122150

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 8
-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 272
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 720
-SubTopic 15
-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 915
-SubTopic 235
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

+ Details

Supplemental Financial Information

3 Months Ended

Mar. 31, 2014

Supplemental Financial Information

Supplemental Financial Information

Note 2 Supplemental Financial Information

Interest Expense, Net

	Three months ended March 31,
(in millions)	2014	2013
Interest expense	$70	$72
Interest income	(5)	(6)
Interest expense, net	$65	$66

Inventories

(in millions)	March 31, 2014	December 31, 2013
Finished goods	$ 424	$485
Work-in-process	439	404
Raw materials	241	261
Inventories, net	$1,104	$1,150

Property and Equipment, Net

(in millions)	March 31, 2014		December 31, 2013
Property and equipment, gross	$7,016		$6,909
Less accumulated depreciation	(4,683	)	(4,611	)
Property and equipment, net	$2,333		$2,298

Depreciation expense for the three months ended March 31, 2014 and 2013 was $89 million and $92 million, respectively.

Earnings Per Share	3 Months Ended
Earnings Per Share	Mar. 31, 2014
Earnings Per Share
Earnings Per Share	Note 3 Earnings Per Share AbbVie calculates earnings per share (EPS) using the more dilutive of the treasury stock or the two-class method. For the three months ended March 31, 2014, the two-class method was more dilutive. As such, the dilutive effect of outstanding restricted stock units (RSUs) and restricted stock awards (RSAs) for the three months ended March 31, 2014 of approximately 4 million shares was excluded from the denominator for the calculation of diluted EPS. These awards otherwise would have been included in the calculation of EPS under the treasury stock method. Additionally, all earnings (distributed and undistributed) allocable to participating securities, including performance-based awards not otherwise included in the calculation of EPS under the treasury stock method, was excluded from the numerator for the calculation of basic and diluted earnings per share under the two-class method. Earnings allocable to participating securities for the three months ended March 31, 2014 was $4 million. For the three months ended March 31, 2014, approximately 1 million common shares issuable under stock-based compensation plans were excluded from the computation of earnings per common share assuming dilution because the effect would have been antidilutive. For the three months ended March 31, 2013, AbbVie determined the treasury stock method to be more dilutive. As a result, the dilutive effect of outstanding stock options as well as the dilutive effect of outstanding RSUs and RSAs of approximately 6 million shares were reflected in the denominator for the calculation of diluted EPS for the three months ended March 31, 2013.

Goodwill and Intangible Assets

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets

Goodwill and Intangible Assets

Note 4 Goodwill and Intangible Assets

Goodwill

The carrying amount of goodwill was $6,271 million and $6,277 million at March 31, 2014 and December 31, 2013, respectively. Changes in the goodwill balance were due to foreign currency translation. As of March 31, 2014, there were no accumulated goodwill impairment losses. Future impairment tests for goodwill will be performed annually in the third quarter, or earlier if indicators of impairment exist.

Intangible Assets, Net

The following table summarizes AbbVie’s intangible assets.

	March 31, 2014			December 31, 2013
(in millions)	Gross carrying amount	Accumulated amortization	Net carrying amount	Gross carrying amount	Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$4,742	$(3,593)	$1,149	$4,744	$(3,503	)	$1,241
License agreements	1,017	(811)	206	994	(792	)	202
Total definite-lived intangible assets	5,759	(4,404)	1,355	5,738	(4,295	)	1,443
Indefinite-lived research and development	447	—	447	447	—		447
Total intangible assets	$6,206	$(4,404)	$1,802	$6,185	$(4,295	)	$1,890

Intangible assets with finite useful lives are amortized over their estimated useful lives. Amortization expense was $110 million and $135 million for the three months ended March 31, 2014 and 2013, respectively, and is included in cost of products sold in the condensed consolidated statements of earnings.

The indefinite-lived intangible assets represent acquired IPR&D associated with products that have not yet received regulatory approval. There were no impairment charges recorded in the three months ended March 31, 2014 and 2013. Future impairment tests for indefinite-lived intangible assets will be performed annually in the third quarter, or earlier if indicators of impairment exist.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

Restructuring Plans

3 Months Ended

Mar. 31, 2014

Restructuring Plans

Restructuring Plans

Note 5 Restructuring Plans

In 2013, AbbVie management approved plans to restructure certain commercial operations in conjunction with the loss and expected loss of exclusivity of certain products. Restructuring charges related to these plans were $2 million for the three months ended March 31, 2014 and were primarily recorded in SG&A in the condensed consolidated statements of earnings.

In 2012 and prior years, AbbVie management approved plans to realign its worldwide manufacturing operations and selected domestic and international commercial and research and development (R&D) operations in order to reduce costs. For the three months ended March 31, 2013, AbbVie incurred restructuring charges of approximately $9 million for employee severance and contractual obligations, with $7 million classified in cost of products sold and $2 million as SG&A expenses.

The following summarizes the cash activity in the restructuring reserve for the first three months of 2014.

(in millions)
Accrued balance at December 31, 2013		$191
2014 restructuring charges		2
Payments and other adjustments		(23)
Accrued balance at March 31, 2014		$170

Financial Instruments and Fair Value Measures

3 Months Ended

Mar. 31, 2014

Financial Instruments and Fair Value Measures

Financial Instruments and Fair Value Measures

Note 6 Financial Instruments and Fair Value Measures

Risk Management Policy

The company is exposed to foreign currency exchange rate and interest rate risks related to its business operations. The company’s hedging policy attempts to manage these risks to an acceptable level based on the company’s judgment of the appropriate trade-off between risk, opportunity and costs. The company uses derivative instruments to reduce its exposure to foreign currency exchange rates. The company is also exposed to the risk that its earnings and cash flows could be adversely impacted by fluctuations in interest rates. The company periodically enters into interest rate swaps, based on judgment, to manage interest costs in which the company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional amount. Derivative instruments are not used for trading purposes or to manage exposure to changes in interest rates for investment securities, and none of the company’s outstanding derivative instruments contain credit risk related contingent features; collateral is generally not required.

Financial Instruments

Various AbbVie foreign subsidiaries enter into foreign currency forward exchange contracts to manage exposures to changes in foreign exchange rates for anticipated intercompany transactions denominated in a currency other than the functional currency of the local entity. These contracts, with notional amounts totaling $2.7 billion and $1.5 billion at March 31, 2014 and December 31, 2013, respectively, are designated as cash flow hedges and are recorded at fair value. Accumulated gains and losses as of March 31, 2014 will be included in cost of products sold at the time the products are sold, generally not exceeding twelve months.

The company enters into foreign currency forward exchange contracts to manage its exposure to foreign currency denominated trade payables and receivables and intercompany loans. The contracts are marked-to-market, and resulting gains or losses are reflected in income and are generally offset by losses or gains on the foreign currency exposure being managed. At March 31, 2014 and December 31, 2013, AbbVie held notional amounts of $6.3 billion and $5.3 billion, respectively, of such foreign currency forward exchange contracts.

AbbVie is a party to interest rate hedge contracts, designated as fair value hedges, totaling $8.0 billion at both March 31, 2014 and December 31, 2013. The effect of the hedge is to change a fixed-rate interest obligation to a floating rate for that portion of the debt. AbbVie recorded the contracts at fair value and adjusted the carrying amount of the fixed-rate debt by an offsetting amount.

The following table summarizes the amounts and location of AbbVie’s derivative instruments as of March 31, 2014.

	Derivatives in asset position		Derivatives in liability position
(in millions)	Fair value	Balance sheet caption	Fair value	Balance sheet caption
Interest rate swaps designated as fair value hedges	$—	n/a	$346	Long-term liabilities
Foreign currency forward exchange contracts —
Hedging instruments	17	Prepaid expenses and other	36	Accounts payable and accrued liabilities
Others not designated as hedges	25	Prepaid expenses and other	35	Accounts payable and accrued liabilities
Total	$42		$417

The following table summarizes the amounts and location of AbbVie’s derivative instruments as of December 31, 2013.

	Derivatives in asset position		Derivatives in liability position
(in millions)	Fair value	Balance sheet caption	Fair value	Balance sheet caption
Interest rate swaps designated as fair value hedges	$—	n/a	$432	Long-term liabilities
Foreign currency forward exchange contracts —
Hedging instruments	—	Prepaid expenses and other	61	Accounts payable and accrued liabilities
Others not designated as hedges	17	Prepaid expenses and other	12	Accounts payable and accrued liabilities
Total	$17		$505

While certain derivatives are subject to netting arrangements with the company’s counterparties, the company does not offset derivative assets and liabilities within the condensed consolidated balance sheets.

The following table summarizes the activity for derivative instruments and the amounts and location of income (expense) and gain (loss) reclassified into income and for certain other derivative instruments for the three months ended March 31, 2014 and 2013, respectively. The amount of hedge ineffectiveness was not significant for the three months ended March 31, 2014 or 2013.

	(Loss) gain recognized in other comprehensive (loss) income		Income (expense) and gain (loss) reclassified into or recorded in net income
(in millions)	2014	2013	2014	2013	Income statement caption
Foreign currency forward exchange contracts —
Designated as cash flow hedges	$21	$9	$(12)	$—	Cost of products sold
Not designated as hedges	n/a	n/a	(1)	(9)	Net foreign exchange loss
Interest rate swaps designated as fair value hedges	n/a	n/a	86	(40)	Interest expense, net

The gain/(loss) related to fair value hedges is recognized in net interest expense and directly offsets the (loss)/gain on the underlying hedged item, the fixed-rate debt, resulting in no net impact to net interest expense for the three months ended March 31, 2014 and 2013.

Fair Value Measures

The fair value hierarchy under the accounting standard for fair value measurements consists of the following three levels.

· Level 1 – Valuations based on unadjusted quoted prices in active markets for identical assets that the company has the ability to access;

· Level 2 – Valuations based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active, and model-based valuations in which all significant inputs are observable in the market; and

· Level 3 – Valuations using significant inputs that are unobservable in the market and include the use of judgment by the company’s management about the assumptions market participants would use in pricing the asset or liability.

The following table summarizes the bases used to measure certain assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheet as of March 31, 2014.

		Basis of fair value measurement
(in millions)	Balance at March 31, 2014	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$8,140	$618	$7,522	$—
Time deposits	960	—	960	—
Equity securities	12	12	—	—
Foreign currency contracts	42	—	42	—
Total assets	$9,154	$630	$8,524	$—
Liabilities
Interest rate hedges	$346	$—	$346	$—
Foreign currency contracts	71	—	71	—
Contingent consideration	27	—	—	27
Total liabilities	$444	$—	$417	$27

The following table summarizes the bases used to measure certain assets and liabilities that are carried at fair value on a recurring basis in the consolidated balance sheet as of December 31, 2013.

		Basis of fair value measurement
(in millions)	Balance at December 31, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$9,595	$684	$8,911	$—
Time deposits	300	—	300	—
Equity securities	10	10	—	—
Foreign currency contracts	17	—	17	—
Total assets	$9,922	$694	$9,228	$—
Liabilities
Interest rate hedges	$432	$—	$432	$—
Foreign currency contracts	73	—	73	—
Contingent consideration	165	—	—	165
Total liabilities	$670	$—	$505	$165

The fair values for time deposits included in cash and equivalents and short-term investments are determined based on a discounted cash flow analysis reflecting quoted market rates for the same or similar instruments. The fair values of time deposits approximate their amortized cost due to the short maturities of these instruments. Available-for-sale equity securities consists of investments for which the fair value is determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. The derivatives entered into by the company are valued using publicized spot curves for interest rate hedges and publicized forward curves for foreign currency contracts. The contingent consideration is valued using a discounted cash flow technique that reflects management’s expectations about probability of payment.

Cumulative unrealized holding gains on available-for-sale equity securities totaled $2 million at both March 31, 2014 and December 31, 2013, respectively.

There have been no transfers of assets or liabilities between the fair value measurement levels. The following table is a reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and investments.

(in millions)
Fair value as of December 31, 2013	$165
Payments	(137	)
Change in fair value recognized in net foreign exchange loss	(1	)
Fair value as of March 31, 2014	$27

In connection with the acquisition of Solvay’s U.S. pharmaceuticals business in 2010, the achievement of a certain sales milestone resulted in a payment of approximately $137 million in the first quarter of 2014 for which a liability was previously established.

In addition to the financial instruments that the company is required to recognize at fair value on the condensed consolidated balance sheets, the company has certain financial instruments that are recognized at historical cost or some basis other than fair value. The carrying values and fair values of certain financial instruments as of March 31, 2014 and December 31, 2013 are shown in the table below.

	Book values		Approximate fair values
(in millions)	March 31, 2014	December 31, 2013	March 31, 2014	December 31, 2013
Assets
Investments	$107	$108	$144	$129
Liabilities
Short-term borrowings	2	413	2	413
Current portion of long-term debt and lease obligations	18	18	18	18
Long-term debt and lease obligations, excluding fair value hedges	14,732	14,724	14,696	14,493

The following table summarizes the bases used to measure the approximate fair values of the financial instruments as of March 31, 2014.

		Basis of fair value measurement
(in millions)	Fair value at March 31, 2014	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Investments	$144	$54	$31	$59
Total assets	$144	$54	$31	$59
Liabilities
Short-term borrowings	$2	$—	$2	$—
Current portion of long-term debt and lease obligations	18	—	18	—
Long-term debt and lease obligations, excluding fair value hedges	14,696	14,609	87	—
Total liabilities	$14,716	$14,609	$107	$—

The following table summarizes the bases used to measure the approximate fair values of the financial instruments as of December 31, 2013.

		Basis of fair value measurement
(in millions)	Fair value at December 31, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Investments	$129	$39	$30	$60
Total assets	$129	$39	$30	$60
Liabilities
Short-term borrowings	$413	$—	$413	$—
Current portion of long-term debt and lease obligations	18	—	18	—
Long-term debt and lease obligations, excluding fair value hedges	14,493	14,413	80	—
Total liabilities	$14,924	$14,413	$511	$—

Investments consist of cost method investments and held-to-maturity debt securities. Cost method investments include certain investments for which the fair value is determined by using the published market price per unit multiplied by the number of units held, without consideration of transaction costs. To determine the fair value of other cost method investments, the company takes into consideration recent transactions, as well as the financial information of the investee, which represents a Level 3 basis of fair value measurement. The fair value of held-to-maturity debt securities was estimated based upon the quoted market prices for the same or similar debt instruments. The fair values of short-term and current borrowings approximate the carrying values due to the short maturities of these instruments.

The fair value of long-term debt, excluding fair value hedges, was determined by using the published market price for the debt instruments, without consideration of transaction costs, which represents a Level 1 basis of fair value measurement. The counterparties to financial instruments consist of select major international financial institutions.

Concentrations of Risk

The company invests excess cash in time deposits, money market funds and U.S. Treasury securities and diversifies the concentration of cash among different financial institutions. The company monitors concentrations of credit risk associated with deposits with financial institutions. Credit exposure limits have been established to limit a concentration with any single issuer or institution.

Three U.S. wholesalers accounted for 34 percent and 38 percent of total net accounts receivable as of March 31, 2014 and December 31, 2013, respectively, and substantially all of AbbVie’s U.S. sales are to these three wholesalers. In addition, net governmental receivables outstanding in Greece, Portugal, Italy and Spain totaled $566 million at March 31, 2014 and $781 million at December 31, 2013.

HUMIRA is AbbVie’s single largest product and accounted for approximately 58 percent and 52 percent of AbbVie’s total net sales in the first three months ended March 31, 2014 and 2013, respectively.

Short-Term Borrowings

At December 31, 2013, short-term borrowings included $400 million of commercial paper borrowings. No commercial paper balances were outstanding as of March 31, 2014. The weighted-average interest rate on the commercial paper was 0.2% for the three months ended March 31, 2014. No borrowings were outstanding under the $2.0 billion unsecured bank credit facility as of March 31, 2014.

Post-Employment Benefits

3 Months Ended

Mar. 31, 2014

Post-Employment Benefits

Post-Employment Benefits

Note 7 Post-Employment Benefits

The following is the summary of net periodic benefit cost relating to the company’s defined benefit and other post-employment plans.

	Defined benefit plans			Other post- employment plans
for the three months ended March 31 (in millions)	2014		2013	2014	2013
Service cost	$43		$47	$5	$6
Interest cost	55		48	6	6
Expected return on plan assets	(75	)	(66)	—	—
Amortization of actuarial losses and prior service costs	17		28	(1)	—
Net periodic benefit cost	$40		$57	$10	$12

AbbVie made voluntary contributions of $370 million in the first quarter of 2014 and $145 million in the first quarter of 2013 to its main domestic defined benefit pension plan.

Equity

3 Months Ended

Mar. 31, 2014

Equity

Equity

Note 8 Equity

Stock-Based Compensation

Stock-based compensation expense was $106 million and $87 million for the three months ended March 31, 2014 and 2013, respectively. For the three months ended March 31, 2014, $68 million of stock-based compensation expense was classified in SG&A, $34 million in R&D and $4 million in cost of products sold. For the three months ended March 31, 2013, $57 million of stock-based compensation expense was classified in SG&A, $25 million in R&D and $5 million in cost of products sold.

Prior to separation, AbbVie employees participated in Abbott’s incentive stock program. The AbbVie 2013 Incentive Stock Program, adopted at the time of separation, facilitated the assumption of certain awards granted under Abbott’s incentive stock program and authorizes the post-separation grant of several different forms of benefits, including nonqualified stock options, RSAs, RSUs and performance-based RSAs and RSUs.

In connection with the separation, outstanding Abbott employee stock options, RSAs and RSUs previously issued under Abbott’s incentive stock program were adjusted and converted into new Abbott and AbbVie stock-based awards using a formula designed to preserve the intrinsic value and fair value of the awards immediately prior to the separation. Upon the separation on January 1, 2013, holders of Abbott stock options, RSAs and RSUs generally received one AbbVie stock-based award for each Abbott stock-based award outstanding. These adjusted awards retained the vesting schedule and expiration date of the original awards. No awards have been granted to Abbott employees other than in connection with the separation.

Stock Options

AbbVie determines the fair value of stock options using the Black-Scholes model. The assumptions used in estimating the fair value of stock options granted during the three months ended March 31, 2014 and 2013, along with the grant-date fair value, were as follows.

	Three months ended March 31,
	2014	2013
Risk-free interest rate	1.9%	1.1%
Average life of options (years)	6.0	6.0
Volatility	27.01%	32.63%
Dividend yield	3.2%	4.3%
Fair value per stock option	$9.83	$6.87

The following table summarizes AbbVie stock option activity for both AbbVie and Abbott employees for the three months ended March 31, 2014.

(options in thousands, aggregate intrinsic value in millions)	Options		Weighted- average exercise price	Weighted- average remaining life (in years)	Aggregate intrinsic value
Outstanding at December 31, 2013	35,994		$27.48
Granted	1,035		51.92
Exercised	(3,274	)	28.86
Lapsed	(49	)	23.89
Outstanding at March 31, 2014	33,706		28.10	3.8	$786
Exercisable at March 31, 2014	30,967		$27.02	3.3	$756

The aggregate intrinsic value in the table above represents the difference between the exercise price and the company’s closing stock price on the last day of trading for the three months ended March 31, 2014. The total intrinsic value of options exercised in the three months ended March 31, 2014 and 2013 was $72 million and $42 million, respectively.

As of March 31, 2014, $5 million of unrecognized compensation cost related to stock options is expected to be recognized as expense over approximately the next two years.

RSAs & RSUs

The following table summarizes AbbVie RSA and RSU activity (including performance-based awards) for both AbbVie and Abbott employees for the three months ended March 31, 2014.

(share units in thousands)	Share units		Weighted-average grant date fair value
Outstanding at December 31, 2013	14,910		$32.07
Granted	4,482		51.23
Vested	(6,193	)	29.05
Lapsed	(124	)	32.71
Outstanding at March 31, 2014	13,075		$ 40.04
Unvested shares at March 31, 2014	12,771		$ 40.23

The fair value of RSAs and RSUs (including performance-based awards) is determined based on the number of shares granted and the quoted price of the company’s common stock on the date of the grant. The fair market value of RSAs and RSUs vested in the three months ended March 31, 2014 and 2013 was $314 million and $267 million, respectively. As of March 31, 2014, $280 million of unrecognized compensation cost related to RSAs and RSUs is expected to be recognized as expense over approximately the next two years.

Cash Dividends

On February 20, 2014, the board of directors declared a quarterly cash dividend of $0.42 per share, which represented an increase of 5 percent over the previous quarterly rate of $0.40 per share. The dividend is payable May 15, 2014 to stockholders of record at the close of business on April 15, 2014. Additionally, the quarterly cash dividend declared by the board of directors on December 12, 2013 of $0.40 per share of common stock for stockholders of record on January 15, 2014 was paid on February 14, 2014.

On January 4 and February 15, 2013, the board of directors declared quarterly cash dividends of $0.40 per share of common stock, which were paid on February 15 and May 15, 2013, respectively. The cash dividend of $0.40 per share of common stock declared on January 4, 2013 was declared from pre-separation earnings and was recorded as a reduction of additional paid-in capital.

Stock Repurchase Program

On February 15, 2013, AbbVie’s board of directors authorized a $1.5 billion stock repurchase program. Purchases of AbbVie shares may be made from time to time at management’s discretion depending on the company’s cash flows, net debt level and market conditions. The plan has no time limit and can be discontinued at any time. During the three months ended March 31, 2014, AbbVie repurchased approximately 5 million shares for $250 million in the open market. Shares repurchased under this program are recorded at acquisition cost, including related expenses, and are available for general corporate purposes. AbbVie’s remaining share repurchase authorization is $1.0 billion as of March 31, 2014. There were no share repurchases in the first quarter of 2013.

Accumulated Other Comprehensive Loss

The following table summarizes the changes in balances of each component of accumulated other comprehensive loss, net of tax for the three months ended March 31, 2014.

(in millions) (brackets denote losses)	Foreign currency translation adjustments	Pension and post- employment benefits	Unrealized gains (losses) on marketable equity securities	Gains (losses) on hedging activities	Total
Balance as of December 31, 2013	$470	$(827)	$2	$(87)	$(442)
Other comprehensive (loss) income before reclassifications	(29)	—	—	21	(8)
Amounts reclassified from accumulated other comprehensive loss	—	12	—	12	24
Net current-period other comprehensive (loss) income	(29)	12	—	33	16
Balance as of March 31, 2014	$441	$(815)	$2	$(54)	$(426)

The table below presents the significant amounts reclassified out of each component of accumulated other comprehensive loss for the three months ended March 31, 2014.

Type of reclassification (brackets denote loss)	Amount reclassified from accumulated other comprehensive loss (in millions)	Affected line item in the condensed consolidated statement of earnings
Pension and post-employment benefits
Amortization of actuarial losses and other	16	(a)
Tax expense	(4)
Total reclassification for the three months ended March 31, 2014, net of tax	$12

(a) Components are included in computation of net periodic benefit cost (see Note 7 for details)

Income Taxes	3 Months Ended
Income Taxes	Mar. 31, 2014
Income Taxes
Income Taxes	Note 9 Income Taxes The effective income tax rates were 23.8 percent and 21.9 percent in the first quarters of 2014 and 2013, respectively. The effective tax rates in both periods were less than the statutory federal income tax rate of 35 percent primarily due to the benefit of lower income tax rates in locations outside the United States and tax exemptions and incentives in Puerto Rico and other foreign tax jurisdictions. The increase in the effective tax rate in the first quarter of 2014 over the prior year was principally due to changes in the jurisdictional mix of earnings. It is reasonably possible during the next twelve months that uncertain tax positions may be settled, and the gross unrecognized tax benefits balance may change up to $22 million. AbbVie and Abbott entered into a tax sharing agreement effective on the date of separation. For tax contingencies prior to the separation, Abbott will indemnify and hold AbbVie harmless if the tax positions are settled for amounts in excess of recorded liabilities, and AbbVie will not benefit if prior tax positions are resolved more favorably than recorded amounts.

Legal Proceedings and Contingencies	3 Months Ended
Legal Proceedings and Contingencies	Mar. 31, 2014
Legal Proceedings and Contingencies
Legal Proceedings and Contingencies	Note 10 Legal Proceedings and Contingencies Subject to certain exceptions specified in the separation agreement, AbbVie assumed the liability for, and control of, all pending and threatened legal matters related to its business, including liabilities for any claims or legal proceedings related to products that had been part of its business but were discontinued prior to the distribution, as well as assumed or retained liabilities, and will indemnify Abbott for any liability arising out of or resulting from such assumed legal matters. AbbVie is involved in various claims, legal proceedings and investigations, including those described below. The recorded accrual balance for litigation at March 31, 2014 was not significant. Within the next year, other legal proceedings may occur that may result in a change in the estimated loss accrued by AbbVie. While it is not feasible to predict the outcome of all other proceedings and exposures with certainty, management believes that their ultimate disposition should not have a material adverse effect on AbbVie’s consolidated financial position, cash flows, or results of operations. Lawsuits have been filed against AbbVie and others generally alleging that the 2005 patent litigation settlement involving Niaspan® entered into between Kos Pharmaceuticals, Inc. (a company acquired by Abbott Laboratories in 2006 and presently a subsidiary of AbbVie) and a generic company violates federal and state antitrust laws and state unfair and deceptive trade practices and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. In September 2013, all of these pending putative class action lawsuits were centralized for consolidated or coordinated pre-trial proceedings in the United States District Court for the Eastern District of Pennsylvania under the Multi-District Litigation Rules as In re Niaspan Antitrust Litigation, MDL No. 2460. In August 2013, a putative class action lawsuit, Sidney Hillman Health Center of Rochester, et al. v. AbbVie Inc., et al., was filed against AbbVie in the United States District Court for the Northern District of Illinois by three healthcare benefit providers alleging violations of federal RICO statutes and state deceptive business practice and unjust enrichment laws in connection with reimbursements for certain uses of Depakote from 1998 to 2012. Plaintiffs seek monetary damages and/or equitable relief and attorneys’ fees. Several pending lawsuits filed against Unimed Pharmaceuticals, Inc., Solvay Pharmaceuticals, Inc. (a company Abbott acquired in February 2010 and now known as AbbVie Products LLC) and others were consolidated for pre-trial purposes in the United States District Court for the Northern District of Georgia under the Multi District Litigation Rules as In re AndroGel Antitrust Litigation, MDL No. 2084. These cases, brought by private plaintiffs and the Federal Trade Commission (FTC), generally allege Solvay’s 2006 patent litigation involving AndroGel was sham litigation and the patent litigation settlement agreement and related agreements with three generic companies violate federal and state antitrust laws and state consumer protection and unjust enrichment laws. Plaintiffs generally seek monetary damages and/or injunctive relief and attorneys’ fees. MDL 2084 includes: (a) three individual plaintiff lawsuits; (b) seven purported class actions; and (c) Federal Trade Commission v. Watson Pharmaceuticals, Inc. et al., filed in May 2009 in the United States District Court for the Northern District of Georgia. Following the district court’s dismissal of all plaintiffs’ claims, the FTC’s appeal led to its claim regarding the patent litigation settlement being reinstated. In February 2014, the United States Court of Appeals for the Eleventh Circuit remanded the private plaintiffs’ claims regarding the patent litigation settlement, which are proceeding with the FTC’s in discovery in the district court. AbbVie is seeking to enforce its patent rights relating to testosterone gel (a drug AbbVie sells under the trademark AndroGel® 1.62%). In a case filed in the United States District Court for the District of Delaware in February 2013, AbbVie alleges that Perrigo Company’s and Perrigo Israel Pharmaceutical Ltd.’s proposed generic product infringes AbbVie patents and seeks declaratory and injunctive relief. In a second case filed in the United States District Court for the District of Delaware in March 2013, AbbVie alleges that Watson Laboratories Inc.’s and Actavis Inc.’s proposed generic product infringes AbbVie’s patents and seeks declaratory and injunctive relief. AbbVie is seeking to enforce its patent rights relating to ritonavir/lopinavir tablets (a drug AbbVie sells under the trademark Kaletra®). In a case filed in the United States District Court for the Northern District of Illinois in March 2009, AbbVie alleges that Matrix Laboratories, Inc.’s, Matrix Laboratories, Ltd.’s, and Mylan, Inc.’s proposed generic products infringe AbbVie’s patents and seeks declaratory and injunctive relief. Upon Matrix’s motion in November 2009, the court granted a five-year stay of the litigation unless good cause to lift the stay is shown. AbbVie is seeking to enforce its patent rights relating to ritonavir tablets (a drug AbbVie sells under the trademark Norvir®). In a case pending in the United States District Court for the Southern District of Ohio since April 2012, AbbVie alleges that Roxane Laboratories, Inc.’s (Roxane) proposed generic product infringes AbbVie’s patents and seeks declaratory and injunctive relief. In another case filed in the United States District Court for the Southern District of Ohio in July 2013, AbbVie alleges that Roxane’s proposed generic ritonavir product infringes additional AbbVie patents and seeks declaratory and injunctive relief on these additional patents. In a separate case filed in the United States District Court for the District of Delaware in May 2013, AbbVie alleges that Hetero USA Inc.’s and Hetero Labs Limited’s proposed generic ritonavir tablets product infringes AbbVie’s patents and seeks declaratory and injunctive relief. AbbVie is seeking to enforce certain patent rights that cover the use of fully human anti-TNF alpha antibodies with methotrexate to treat rheumatoid arthritis. In a case filed in the United States District Court for the District of Massachusetts in May 2009, AbbVie alleges Centocor Ortho Biotech, Inc.’s (now Janssen Biotech, Inc.’s) product Simponi® infringes AbbVie’s patents and seeks damages and injunctive relief. In November 2007, GlaxoSmithKline filed a lawsuit against Abbott Laboratories in the United States District Court for the Northern District of California alleging that Abbott violated antitrust laws in connection with the 2003 Norvir re-pricing. In March 2011, a jury found that Abbott did not violate antitrust laws, but breached its license agreement with the plaintiff. In January 2014, a 3-judge panel of the United States Court of Appeals for the Ninth Circuit reversed this verdict and remanded the case for a new trial due to the alleged improper exclusion of a potential juror. In March 2014, the Ninth Circuit instructed the parties to file briefs on whether the Ninth Circuit should rehear the case en banc. AbbVie assumed the liability for and control of certain legal matters, including this proceeding, in connection with its separation from Abbott.

Segment Information

3 Months Ended

Mar. 31, 2014

Segment Information

Segment Information

Note 11 Segment Information

AbbVie operates in one business segment—pharmaceutical products. Substantially all of AbbVie’s U.S. sales are to three wholesalers. Outside the United States, products are sold primarily to health care providers or through distributors, depending on the market served. Worldwide net sales of key products were as follows.

	Three months ended March 31,
(in millions)	2014	2013
HUMIRA	$2,637	$2,244
Synagis	354	345
AndroGel	254	240
Kaletra	195	219
Lupron	189	181
Synthroid	157	119
Sevoflurane	142	137
Creon	107	90
Duodopa	52	39
Dyslipidemia products	96	344
All other	380	371
Net sales	$4,563	$4,329

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599

+ Details

Supplemental Financial Information (Tables)

3 Months Ended

Mar. 31, 2014

Supplemental Financial Information

Schedule of interest expense, net

	Three months ended March 31,
(in millions)	2014	2013
Interest expense	$70	$72
Interest income	(5)	(6)
Interest expense, net	$65	$66

Schedule of inventories, net

(in millions)	March 31, 2014	December 31, 2013
Finished goods	$ 424	$485
Work-in-process	439	404
Raw materials	241	261
Inventories, net	$1,104	$1,150

Schedule of property and equipment, net

(in millions)	March 31, 2014		December 31, 2013
Property and equipment, gross	$7,016		$6,909
Less accumulated depreciation	(4,683	)	(4,611	)
Property and equipment, net	$2,333		$2,298

Goodwill and Intangible Assets (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets

Schedule of intangible assets

	March 31, 2014			December 31, 2013
(in millions)	Gross carrying amount	Accumulated amortization	Net carrying amount	Gross carrying amount	Accumulated amortization		Net carrying amount
Definite-lived intangible assets
Developed product rights	$4,742	$(3,593)	$1,149	$4,744	$(3,503	)	$1,241
License agreements	1,017	(811)	206	994	(792	)	202
Total definite-lived intangible assets	5,759	(4,404)	1,355	5,738	(4,295	)	1,443
Indefinite-lived research and development	447	—	447	447	—		447
Total intangible assets	$6,206	$(4,404)	$1,802	$6,185	$(4,295	)	$1,890

Restructuring Plans (Tables)

3 Months Ended

Mar. 31, 2014

Restructuring Plan 2012 and Prior Years

Restructuring Plans

Summary of the cash activity in the restructuring reserve

(in millions)
Accrued balance at December 31, 2013		$191
2014 restructuring charges		2
Payments and other adjustments		(23)
Accrued balance at March 31, 2014		$170

Financial Instruments and Fair Value Measures (Tables)

3 Months Ended

Mar. 31, 2014

Financial Instruments and Fair Value Measures

Schedule of amounts and balance sheet location of derivatives

The following table summarizes the amounts and location of AbbVie’s derivative instruments as of March 31, 2014.

	Derivatives in asset position		Derivatives in liability position
(in millions)	Fair value	Balance sheet caption	Fair value	Balance sheet caption
Interest rate swaps designated as fair value hedges	$—	n/a	$346	Long-term liabilities
Foreign currency forward exchange contracts —
Hedging instruments	17	Prepaid expenses and other	36	Accounts payable and accrued liabilities
Others not designated as hedges	25	Prepaid expenses and other	35	Accounts payable and accrued liabilities
Total	$42		$417

The following table summarizes the amounts and location of AbbVie’s derivative instruments as of December 31, 2013.

	Derivatives in asset position		Derivatives in liability position
(in millions)	Fair value	Balance sheet caption	Fair value	Balance sheet caption
Interest rate swaps designated as fair value hedges	$—	n/a	$432	Long-term liabilities
Foreign currency forward exchange contracts —
Hedging instruments	—	Prepaid expenses and other	61	Accounts payable and accrued liabilities
Others not designated as hedges	17	Prepaid expenses and other	12	Accounts payable and accrued liabilities
Total	$17		$505

Schedule of derivative activity and amounts and locations of income (expense) and gain (loss) reclassified into income

	(Loss) gain recognized in other comprehensive (loss) income		Income (expense) and gain (loss) reclassified into or recorded in net income
(in millions)	2014	2013	2014	2013	Income statement caption
Foreign currency forward exchange contracts —
Designated as cash flow hedges	$21	$9	$(12)	$—	Cost of products sold
Not designated as hedges	n/a	n/a	(1)	(9)	Net foreign exchange loss
Interest rate swaps designated as fair value hedges	n/a	n/a	86	(40)	Interest expense, net

Summary of the bases used to measure certain assets and liabilities that are carried at fair value on a recurring basis in the condensed consolidated balance sheet

		Basis of fair value measurement
(in millions)	Balance at March 31, 2014	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$8,140	$618	$7,522	$—
Time deposits	960	—	960	—
Equity securities	12	12	—	—
Foreign currency contracts	42	—	42	—
Total assets	$9,154	$630	$8,524	$—
Liabilities
Interest rate hedges	$346	$—	$346	$—
Foreign currency contracts	71	—	71	—
Contingent consideration	27	—	—	27
Total liabilities	$444	$—	$417	$27

		Basis of fair value measurement
(in millions)	Balance at December 31, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Cash and equivalents	$9,595	$684	$8,911	$—
Time deposits	300	—	300	—
Equity securities	10	10	—	—
Foreign currency contracts	17	—	17	—
Total assets	$9,922	$694	$9,228	$—
Liabilities
Interest rate hedges	$432	$—	$432	$—
Foreign currency contracts	73	—	73	—
Contingent consideration	165	—	—	165
Total liabilities	$670	$—	$505	$165

Schedule of reconciliation of the fair value measurements that use significant unobservable inputs (Level 3), which consist of contingent payments related to acquisitions and investments

(in millions)
Fair value as of December 31, 2013	$165
Payments	(137	)
Change in fair value recognized in net foreign exchange loss	(1	)
Fair value as of March 31, 2014	$27

Schedule of the carrying values and fair values of certain financial instruments

	Book values		Approximate fair values
(in millions)	March 31, 2014	December 31, 2013	March 31, 2014	December 31, 2013
Assets
Investments	$107	$108	$144	$129
Liabilities
Short-term borrowings	2	413	2	413
Current portion of long-term debt and lease obligations	18	18	18	18
Long-term debt and lease obligations, excluding fair value hedges	14,732	14,724	14,696	14,493

Schedule of fair value of financial instruments by fair value basis

		Basis of fair value measurement
(in millions)	Fair value at March 31, 2014	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Investments	$144	$54	$31	$59
Total assets	$144	$54	$31	$59
Liabilities
Short-term borrowings	$2	$—	$2	$—
Current portion of long-term debt and lease obligations	18	—	18	—
Long-term debt and lease obligations, excluding fair value hedges	14,696	14,609	87	—
Total liabilities	$14,716	$14,609	$107	$—

		Basis of fair value measurement
(in millions)	Fair value at December 31, 2013	Quoted prices in active markets for identical assets (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets
Investments	$129	$39	$30	$60
Total assets	$129	$39	$30	$60
Liabilities
Short-term borrowings	$413	$—	$413	$—
Current portion of long-term debt and lease obligations	18	—	18	—
Long-term debt and lease obligations, excluding fair value hedges	14,493	14,413	80	—
Total liabilities	$14,924	$14,413	$511	$—

Post-Employment Benefits (Tables)

3 Months Ended

Mar. 31, 2014

AbbVie sponsored plans

Employee Benefit Plans

Summary of net periodic benefit cost relating to the company's defined benefit and other post-employment plans

	Defined benefit plans			Other post- employment plans
for the three months ended March 31 (in millions)	2014		2013	2014	2013
Service cost	$43		$47	$5	$6
Interest cost	55		48	6	6
Expected return on plan assets	(75	)	(66)	—	—
Amortization of actuarial losses and prior service costs	17		28	(1)	—
Net periodic benefit cost	$40		$57	$10	$12

Equity (Tables)

3 Months Ended

Mar. 31, 2014

Equity

Schedule of assumptions used in estimating the fair value of stock options granted, along with the grant-date fair value

	Three months ended March 31,
	2014	2013
Risk-free interest rate	1.9%	1.1%
Average life of options (years)	6.0	6.0
Volatility	27.01%	32.63%
Dividend yield	3.2%	4.3%
Fair value per stock option	$9.83	$6.87

Summary of AbbVie stock option activity for both AbbVie and Abbott employees

(options in thousands, aggregate intrinsic value in millions)	Options		Weighted- average exercise price	Weighted- average remaining life (in years)	Aggregate intrinsic value
Outstanding at December 31, 2013	35,994		$27.48
Granted	1,035		51.92
Exercised	(3,274	)	28.86
Lapsed	(49	)	23.89
Outstanding at March 31, 2014	33,706		28.10	3.8	$786
Exercisable at March 31, 2014	30,967		$27.02	3.3	$756

Summary of AbbVie RSA and RSU activity (including performance-based awards) for both AbbVie and Abbott employees

(share units in thousands)	Share units		Weighted-average grant date fair value
Outstanding at December 31, 2013	14,910		$32.07
Granted	4,482		51.23
Vested	(6,193	)	29.05
Lapsed	(124	)	32.71
Outstanding at March 31, 2014	13,075		$ 40.04
Unvested shares at March 31, 2014	12,771		$ 40.23

Summary of changes in balances of each component of accumulated other comprehensive loss

(in millions) (brackets denote losses)	Foreign currency translation adjustments	Pension and post- employment benefits	Unrealized gains (losses) on marketable equity securities	Gains (losses) on hedging activities	Total
Balance as of December 31, 2013	$470	$(827)	$2	$(87)	$(442)
Other comprehensive (loss) income before reclassifications	(29)	—	—	21	(8)
Amounts reclassified from accumulated other comprehensive loss	—	12	—	12	24
Net current-period other comprehensive (loss) income	(29)	12	—	33	16
Balance as of March 31, 2014	$441	$(815)	$2	$(54)	$(426)

Schedule of the significant amounts reclassified out of each component of accumulated other comprehensive loss

Type of reclassification (brackets denote loss)	Amount reclassified from accumulated other comprehensive loss (in millions)	Affected line item in the condensed consolidated statement of earnings
Pension and post-employment benefits
Amortization of actuarial losses and other	16	(a)
Tax expense	(4)
Total reclassification for the three months ended March 31, 2014, net of tax	$12

(a) Components are included in computation of net periodic benefit cost (see Note 7 for details)

Segment Information (Tables)

3 Months Ended

Mar. 31, 2014

Segment Information

Schedule of consolidated financial information by segment

	Three months ended March 31,
(in millions)	2014	2013
HUMIRA	$2,637	$2,244
Synagis	354	345
AndroGel	254	240
Kaletra	195	219
Lupron	189	181
Synthroid	157	119
Sevoflurane	142	137
Creon	107	90
Duodopa	52	39
Dyslipidemia products	96	344
All other	380	371
Net sales	$4,563	$4,329

Background and Basis of Presentation (Details) $ in Millions		3 Months Ended
	Jan. 02, 2013	Mar. 31, 2014 USD ($) customer	Mar. 31, 2013 USD ($)	Dec. 31, 2013 USD ($)
Background and Basis of Presentation
Number of wholesalers \| customer		3
Common stock distribution ratio	1
Separation-related expenses		$ 80	$ 34
Operations and assets (net of liabilities) on which legal transfer of did not occur with the separation of the entity
Accounts receivable		3,650		$ 3,854
Accounts payable and accrued liabilities		6,196		6,448
AbbVie common stock
Background and Basis of Presentation
Percentage of outstanding common stock distributed to Abbott Laboratories' shareholders	100.00%
Abbott
Operations and assets (net of liabilities) on which legal transfer of did not occur with the separation of the entity
Accounts receivable		540		738
Accounts payable and accrued liabilities		$ 517		876
Abbott \| Transition services agreement
Background and Basis of Presentation
Term by which the agreement can be extended		1 year
Abbott \| Transition services agreement \| Maximum
Background and Basis of Presentation
Term for which transition services may be provided post-separation		24 months
Abbott \| Separation agreement
Operations and assets (net of liabilities) on which legal transfer of did not occur with the separation of the entity
Net sales		$ 67
Accounts receivable		68		62
Inventories		47		190
Other assets		63		93
Accounts payable and other accrued liabilities		$ 129		$ 212

Supplemental Financial Information (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Interest Expense, Net
Interest expense	$ 70	$ 72
Interest income	(5)	(6)
Interest expense, net	65	66
Inventories
Finished goods	424		$ 485
Work-in-process	439		404
Raw materials	241		261
Inventories, net	1,104		1,150
Property and Equipment, Net
Property and equipment, gross	7,016		6,909
Less accumulated depreciation	(4,683)		(4,611)
Property and equipment, net	2,333		$ 2,298
Depreciation expense	$ 89	$ 92

Earnings Per Share (Details) - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Anti-dilutive securities excluded from the computation of earnings per common share
Earnings allocable to participating securities (in dollars)	$ 4
Dilutive effect of outstanding stock options, RSUs and RSAs (in shares)		6
RSAs & RSUs
Anti-dilutive securities excluded from the computation of earnings per common share
Anti-dilutive securities excluded from the computation of earnings per common share (in shares)	4
Stock-based compensation plans
Anti-dilutive securities excluded from the computation of earnings per common share
Anti-dilutive securities excluded from the computation of earnings per common share (in shares)	1

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Goodwill
Carrying amount of goodwill	$ 6,271		$ 6,277
Accumulated goodwill impairment losses	0
Definite-lived intangible assets
Gross carrying amount	5,759		5,738
Accumulated amortization	(4,404)		(4,295)
Net carrying amount	1,355		1,443
Indefinite-lived research and development	447		447
Net carrying amount - Indefinite-lived research and development	447		447
Total intangible assets gross carrying amount	6,206		6,185
Accumulated amortization - Total intangible assets	(4,404)		(4,295)
Total intangible assets	1,802		1,890
Amortization of intangible assets	110	$ 135
Impairment charges	0	$ 0
Developed product rights
Definite-lived intangible assets
Gross carrying amount	4,742		4,744
Accumulated amortization	(3,593)		(3,503)
Net carrying amount	1,149		1,241
License agreements
Definite-lived intangible assets
Gross carrying amount	1,017		994
Accumulated amortization	(811)		(792)
Net carrying amount	$ 206		$ 202

Restructuring Plans (Details ) - USD ($) $ in Millions	3 Months Ended
Restructuring Plans (Details ) - USD ($) $ in Millions	Mar. 31, 2014	Mar. 31, 2013
Selling, general and administrative expense
Restructuring Plans
Restructuring charges	$ 2
Restructuring reserve activity
Restructuring charges	2
Restructuring Plan 2012 and Prior Years \| Employee severance and contractual obligations
Restructuring Plans
Restructuring charges	2	$ 9
Restructuring reserve activity
Accrued balance beginning of the period	191
Restructuring charges	2	9
Payments and other adjustments	(23)
Accrued balance end of the period	$ 170
Restructuring Plan 2012 and Prior Years \| Selling, general and administrative expense \| Employee severance and contractual obligations
Restructuring Plans
Restructuring charges		2
Restructuring reserve activity
Restructuring charges		2
Restructuring Plan 2012 and Prior Years \| Cost of products sold \| Employee severance and contractual obligations
Restructuring Plans
Restructuring charges		7
Restructuring reserve activity
Restructuring charges		$ 7

Financial Instruments and Fair Value Measures (Details) $ in Millions	3 Months Ended
	Mar. 31, 2014 USD ($) item	Dec. 31, 2013 USD ($)
Financial Instruments and Fair Value Measures
Number of outstanding derivative instruments containing credit risk contingent features \| item	0
Derivative instruments, notional amount and fair value
Derivatives in asset position	$ 42	$ 17
Derivatives in liability position	417	505
Designated as hedging instrument \| Interest rate contracts \| Fair value hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	8,000	8,000
Designated as hedging instrument \| Interest rate contracts \| Fair value hedges \| Long-term liabilities
Derivative instruments, notional amount and fair value
Derivatives in liability position	346	432
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Derivatives in asset position	17
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Derivatives in liability position	36	61
Designated as hedging instrument \| Foreign currency forward exchange contracts \| Cash flow hedges
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 2,700	1,500
Approximate length of time over which accumulated gains and losses will be recognized in Cost of products sold	12 months
Not designated as hedging instrument \| Foreign currency forward exchange contracts
Derivative instruments, notional amount and fair value
Notional amount of derivative instruments	$ 6,300	5,300
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Prepaid expenses and other
Derivative instruments, notional amount and fair value
Derivatives in asset position	25	17
Not designated as hedging instrument \| Foreign currency forward exchange contracts \| Accounts payable and accrued liabilities
Derivative instruments, notional amount and fair value
Derivatives in liability position	$ 35	$ 12

Financial Instruments and Fair Value Measures (Details 2) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Interest rate contracts \| Fair value hedges \| Interest expense, net
Gain (loss) on derivatives
Income (expense) and gain (loss) reclassified into or recorded in net income	$ 86	$ (40)
Foreign currency forward exchange contracts \| Not designated as hedging instrument \| Net foreign exchange loss
Gain (loss) on derivatives
Income (expense) and gain (loss) reclassified into or recorded in net income	(1)	(9)
Foreign currency forward exchange contracts \| Cash flow hedges \| Cost of products sold
Gain (loss) on derivatives
(Loss) gain recognized in other comprehensive (loss) income	21	$ 9
Income (expense) and gain (loss) reclassified into or recorded in net income	$ (12)

Financial Instruments and Fair Value Measures (Details 3) - USD ($) $ in Millions	Mar. 31, 2014	Dec. 31, 2013
Liabilities
Cumulative unrealized holding gains on available-for-sale equity securities	$ 2	$ 2
Fair value
Assets
Short term investments	144	129
Total assets	144	129
Liabilities
Total liabilities	14,716	14,924
Quoted prices in active markets for identical assets (Level 1)
Assets
Short term investments	54	39
Total assets	54	39
Liabilities
Total liabilities	14,609	14,413
Significant other observable inputs (Level 2)
Assets
Short term investments	31	30
Total assets	31	30
Liabilities
Total liabilities	107	511
Significant unobservable inputs (Level 3)
Assets
Short term investments	59	60
Total assets	59	60
Recurring \| Fair value
Assets
Cash and equivalents	8,140	9,595
Equity securities	12	10
Foreign currency contracts	42	17
Total assets	9,154	9,922
Liabilities
Interest rate hedges	346	432
Foreign currency hedges	71	73
Contingent consideration	27	165
Total liabilities	444	670
Recurring \| Fair value \| Time deposits
Assets
Short term investments	960	300
Recurring \| Quoted prices in active markets for identical assets (Level 1)
Assets
Cash and equivalents	618	684
Equity securities	12	10
Total assets	630	694
Recurring \| Significant other observable inputs (Level 2)
Assets
Cash and equivalents	7,522	8,911
Foreign currency contracts	42	17
Total assets	8,524	9,228
Liabilities
Interest rate hedges	346	432
Foreign currency hedges	71	73
Total liabilities	417	505
Recurring \| Significant other observable inputs (Level 2) \| Time deposits
Assets
Short term investments	960	300
Recurring \| Significant unobservable inputs (Level 3)
Liabilities
Contingent consideration	27	165
Total liabilities	$ 27	$ 165

Financial Instruments and Fair Value Measures (Details 4) $ in Millions	3 Months Ended
	Mar. 31, 2014 USD ($)
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Fair value at the beginning of the period	$ 165
Payments	(137)
Change in fair value recognized in net foreign exchange loss	(1)
Fair value at the end of the period	27
Transfers of assets or liabilities between the fair value measurement levels
Transfer of assets from level 1 to level 2	0
Transfer of assets from level 2 to level 1	0
Transfer of liabilities from level 1 to level 2	0
Transfer of liabilities from level 2 to level 1	0
Contingent payments related to acquisitions \| Solvay SA Pharmaceuticals
Reconciliation of the fair value measurements that use significant unobservable inputs (Level 3)
Payments	$ 137

Financial Instruments and Fair Value Measures (Details 5) - USD ($) $ in Millions	Mar. 31, 2014	Dec. 31, 2013
Book values
Assets
Investments	$ 107	$ 108
Liabilities
Short-term borrowings	2	413
Current portion of long-term debt and lease obligations	18	18
Long-term debt and lease obligations, excluding fair value hedges	14,732	14,724
Approximate fair values
Assets
Investments	144	129
Liabilities
Short-term borrowings	2	413
Current portion of long-term debt and lease obligations	18	18
Long-term debt and lease obligations, excluding fair value hedges	$ 14,696	$ 14,493

Financial Instruments and Fair Value Measures (Details 6) - USD ($) $ in Millions	Mar. 31, 2014	Dec. 31, 2013
Fair value
Assets
Investments	$ 144	$ 129
Total assets	144	129
Liabilities
Short-term borrowings	2	413
Current portion of long-term debt and lease obligations	18	18
Long-term debt and lease obligations, excluding fair value hedges	14,696	14,493
Total liabilities	14,716	14,924
Quoted prices in active markets for identical assets (Level 1)
Assets
Investments	54	39
Total assets	54	39
Liabilities
Long-term debt and lease obligations, excluding fair value hedges	14,609	14,413
Total liabilities	14,609	14,413
Significant other observable inputs (Level 2)
Assets
Investments	31	30
Total assets	31	30
Liabilities
Short-term borrowings	2	413
Current portion of long-term debt and lease obligations	18	18
Long-term debt and lease obligations, excluding fair value hedges	87	80
Total liabilities	107	511
Significant unobservable inputs (Level 3)
Assets
Investments	59	60
Total assets	$ 59	$ 60

Financial Instruments and Fair Value Measures (Details 7) $ in Millions	3 Months Ended		12 Months Ended
	Mar. 31, 2014 USD ($) customer	Mar. 31, 2013	Dec. 31, 2013 USD ($)
Concentration of Risk
Number of principal customers	3
Governmental accounts in Greece, Portugal, Italy and Spain
Concentration of Risk
Net governmental receivables outstanding \| $	$ 566		$ 781
Net accounts receivables
Concentration of Risk
Number of principal customers	3
Net accounts receivables \| U.S. wholesalers
Concentration of Risk
Concentrations risk (as a percent)	34.00%		38.00%
Total sales \| HUMIRA
Concentration of Risk
Concentrations risk (as a percent)	58.00%	52.00%

Financial Instruments and Fair Value Measures (Details 8) - USD ($) $ in Millions	Mar. 31, 2014	Dec. 31, 2013
Short-Term Borrowings
Short-term borrowings	$ 2	$ 413
Commercial paper
Short-Term Borrowings
Short-term borrowings	$ 0	$ 400
Weighted-average interest rate (as a percent)	0.20%
Unsecured bank credit facility
Short-Term Borrowings
Borrowings outstanding under the company's credit facility	$ 0
Borrowing capacity	$ 2,000

Post-Employment Benefits (Details) - AbbVie Sponsored Plans - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Post-Employment Benefits
Contributions by employer	$ 370	$ 145
Defined benefit plans
Post-Employment Benefits
Service cost	43	47
Interest cost	55	48
Expected return on plan assets	(75)	(66)
Amortization of actuarial losses and prior service costs	17	28
Net periodic benefit cost	40	57
Other post-employment plans
Post-Employment Benefits
Service cost	5	6
Interest cost	6	6
Amortization of actuarial losses and prior service costs	(1)
Net periodic benefit cost	$ 10	$ 12

Equity (Details) $ / shares in Units, shares in Thousands, $ in Millions		3 Months Ended		12 Months Ended
	Jan. 02, 2013 item	Mar. 31, 2014 USD ($) $ / shares shares	Mar. 31, 2013 USD ($) $ / shares	Dec. 31, 2013 $ / shares shares
Stock-Based Compensation
Stock compensation expense recognized \| $		$ 106	$ 87
Abbott
Stock-Based Compensation
Number of awards received in connection with the separation \| item	1
Number of awards granted to employees other than in connection with the separation \| shares		0
Stock Options
Assumptions on which the expense related to stock options granted is based
Risk-free interest rate (as a percent)		1.90%	1.10%
Average life of options		6 years	6 years
Volatility (as a percent)		27.01%	32.63%
Dividend yield (as a percent)		3.20%	4.30%
Fair value per stock option (in dollars per share) \| $ / shares		$ 9.83	$ 6.87
Options
Outstanding at the beginning of the period (in shares) \| shares		35,994
Granted (in shares) \| shares		1,035
Exercised (in shares) \| shares		(3,274)
Lapsed (in shares) \| shares		(49)
Outstanding at the end of the period (in shares) \| shares		33,706		35,994
Exercisable at the end of the period (in shares) \| shares		30,967
Weighted average exercise price
Outstanding at the beginning of the period (in dollars per share) \| $ / shares		$ 27.48
Granted (in dollars per share) \| $ / shares		51.92
Exercised (in dollars per share) \| $ / shares		28.86
Lapsed (in dollars per share) \| $ / shares		23.89
Outstanding at the end of the period (in dollars per share) \| $ / shares		28.10		$ 27.48
Exercisable at the end of the period (in dollars per share) \| $ / shares		$ 27.02
Weighted-Average remaining life (in years)
Outstanding at the end of the period		3 years 9 months 18 days
Exercisable at end of the period		3 years 3 months 18 days
Aggregate intrinsic value
Outstanding at the end of the period \| $		$ 786
Exercisable at the end of the period \| $		756
Additional information
Unrecognized compensation cost \| $		$ 5
Period for recognition of unrecognized compensation cost		2 years
Aggregate intrinsic value of options exercised \| $		$ 72	$ 42
RSAs & RSUs
Additional information
Period for recognition of unrecognized compensation cost		2 years
Share units
Outstanding at the beginning of the period (in shares) \| shares		14,910
Granted (in shares) \| shares		4,482
Vested (in shares) \| shares		(6,193)
Lapsed (in shares) \| shares		(124)
Outstanding at the end of the period (in shares) \| shares		13,075		14,910
Unvested shares at the end of the period (in shares) \| shares		12,771
Weighted average grant date fair value
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue \| $ / shares		$ 40.04		$ 32.07
Granted (in dollars per share) \| $ / shares		51.23
Vested (in dollars per share) \| $ / shares		29.05
Lapsed (in dollars per share) \| $ / shares		32.71
ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageGrantDateFairValue \| $ / shares		40.04		$ 32.07
Unvested shares at the end of the period (in dollars per share) \| $ / shares		$ 40.23
Additional information
Fair market value of awards vested \| $		$ 314	267
Unrecognized compensation cost \| $		280
Selling, general and administrative expense
Stock-Based Compensation
Stock compensation expense recognized \| $		68	57
Research and development
Stock-Based Compensation
Stock compensation expense recognized \| $		34	25
Cost of products sold
Stock-Based Compensation
Stock compensation expense recognized \| $		$ 4	$ 5

Equity (Details 2) - $ / shares

3 Months Ended

Feb. 14, 2014

May 15, 2013

Feb. 15, 2013

Jan. 04, 2013

Mar. 31, 2014

Dec. 31, 2013

Mar. 31, 2013

Cash Dividends

Dividends declared (in dollars per share)

^[1]

$ 0.42

$ 0.80

Pre-separation earnings

Dividends Payable

Date declared

Jan. 04, 2013

Date paid

Feb. 15, 2013

Cash Dividends

Dividends declared (in dollars per share)

$ 0.40

Dividends paid (in dollars per share)

$ 0.40

Quarter One

Dividends Payable

Date declared

Feb. 20, 2014

Feb. 15, 2013

Date of record

Apr. 15, 2014

Date paid

May 15, 2014

May 15, 2013

Cash Dividends

Dividends declared (in dollars per share)

$ 0.42

$ 0.40

Dividends paid (in dollars per share)

$ 0.40

Percentage increase in dividends declared

5.00%

Quarter Four

Dividends Payable

Date declared

Dec. 12, 2013

Date of record

Jan. 15, 2014

Date paid

Feb. 14, 2014

Cash Dividends

Dividends declared (in dollars per share)

$ 0.40

Dividends paid (in dollars per share)

$ 0.40

[1]

Equity (Details 3) - USD ($) shares in Millions, $ in Millions		3 Months Ended
	Feb. 15, 2013	Mar. 31, 2014	Mar. 31, 2013
Stock Repurchase Program
Amount authorized under stock repurchase program	$ 1,500
Shares repurchased		5	0
Payment for shares repurchased on the open market		$ 250
Share repurchase authorization amount remaining		1,000
Changes in accumulated other comprehensive Income
Beginning balance		(442)
Other comprehensive (loss) income before reclassifications		(8)
Amounts reclassified from accumulated other comprehensive income		24
Other comprehensive income (loss)		16	$ (205)
Ending balance		(426)
Foreign currency translation adjustments
Changes in accumulated other comprehensive Income
Beginning balance		470
Other comprehensive (loss) income before reclassifications		(29)
Other comprehensive income (loss)		(29)
Ending balance		441
Pension and post-employment benefits
Changes in accumulated other comprehensive Income
Beginning balance		(827)
Amounts reclassified from accumulated other comprehensive income		12
Other comprehensive income (loss)		12
Ending balance		(815)
Unrealized gains (losses) on marketable equity securities
Changes in accumulated other comprehensive Income
Beginning balance		2
Ending balance		2
Gains (losses) on hedging activities
Changes in accumulated other comprehensive Income
Beginning balance		(87)
Other comprehensive (loss) income before reclassifications		21
Amounts reclassified from accumulated other comprehensive income		12
Other comprehensive income (loss)		33
Ending balance		$ (54)

Equity (Details 4) - USD ($) $ in Millions	3 Months Ended
Equity (Details 4) - USD ($) $ in Millions	Mar. 31, 2014	Mar. 31, 2013
Significant amounts reclassified out of each component of accumulated other comprehensive loss
Tax expense	$ 306	$ 271
Net earnings	980	$ 968
Amount reclassified from accumulated other comprehensive loss
Significant amounts reclassified out of each component of accumulated other comprehensive loss
Net earnings	12
Pension and post-employment benefits \| Amount reclassified from accumulated other comprehensive loss
Significant amounts reclassified out of each component of accumulated other comprehensive loss
Amortization of actuarial losses and other	16
Tax expense	$ (4)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended
Income Taxes (Details) - USD ($) $ in Millions	Mar. 31, 2014	Mar. 31, 2013
Income Taxes
Effective income tax rate (as a percent)	23.80%	21.90%
Statutory tax rate (as a percent)	35.00%	35.00%
Reasonably possible amount that gross unrecognized tax benefits may change within the next twelve months, high end of range	$ 22

Legal Proceedings and Contingencies (Details) - item	1 Months Ended		3 Months Ended
Legal Proceedings and Contingencies (Details) - item	Aug. 31, 2013	Nov. 30, 2009	Mar. 31, 2014
Depakote \| Sidney Hillman Health Center of Rochester, et al. v. AbbVie Inc., et al.
Legal Proceedings and Contingencies
Number of healthcare benefit providers who filed lawsuits	3
Number of generic companies with whom certain litigation related agreements were entered into			3
HUMIRA patent infringement claim, NYU and Centocor \| AndroGel Antitrust Litigation
Legal Proceedings and Contingencies
Number of individual plaintiff lawsuits			3
Number of purported class actions			7
Allegation of proposed generic products infringing AbbVie's patents and seeking declaratory and injunctive relief \| Matrix Laboratories, Inc.'s, Matrix Laboratories, Ltd.'s, and Mylan, Inc.'s case
Legal Proceedings and Contingencies
Stay period		5 years

Segment Information (Details) $ in Millions	3 Months Ended
Segment Information (Details) $ in Millions	Mar. 31, 2014 USD ($) customer segment	Mar. 31, 2013 USD ($)
Segment Information
Number of Operating Segments \| segment	1
Number of principal customers \| customer	3
Segment and Geographic Area Information
Net sales	$ 4,563	$ 4,329
HUMIRA
Segment and Geographic Area Information
Net sales	2,637	2,244
Synagis
Segment and Geographic Area Information
Net sales	354	345
AndroGel
Segment and Geographic Area Information
Net sales	254	240
Kaletra
Segment and Geographic Area Information
Net sales	195	219
Lupron
Segment and Geographic Area Information
Net sales	189	181
Synthroid
Segment and Geographic Area Information
Net sales	157	119
Sevoflurane
Segment and Geographic Area Information
Net sales	142	137
Creon
Segment and Geographic Area Information
Net sales	107	90
Duodopa
Segment and Geographic Area Information
Net sales	52	39
Dyslipidemia products
Segment and Geographic Area Information
Net sales	96	344
All other
Segment and Geographic Area Information
Net sales	$ 380	$ 371